Here is a short history lesson for those who believe the insulin pump market is set for consolidation. May 2001 Medtronic acquires MiniMed for a whopping $3.7 Billion, February 2003 Roche buys Disetronic for $1.2 Billion and December 2005 JNJ buys Animas for a partly $518 million. You may have noticed that of the three major deals in the space only MiniMed remains.
You might also notice that MiniMed once seated firmly on the Iron Throne has been replaced by Insulet and that Tandem once a strong contender for the Throne has been regulated to also ran status . . .
This content is restricted to subscribers. Please subscribe.
Already have an account? Please login.